BOSTON and LONDON, September 19, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
PRESS RELEASES
Frequent IVI Complications
Frequent injections in the eye can cause infection, inflammation, and glaucoma. Akari is developing PAS-nomacopan with potential for 4 or fewer doses a year for …
Frequent IVI Burdens
Patients experience significant burdens (fear, discomfort, disruptions to their lives) with geographic atrophy (GA) treatments that are dosed monthly or every …